文献速递临床免疫临床生化质量管理与危急值

特应性皮炎的免疫分析生物标志物

Immunoassay-based biomarkers in atopic dermatitis.
PubMed 文献 · Clin Chim Acta · 2025-10-09

本文综述了基于免疫分析的特应性皮炎(AD)生物标志物,包括TARC/CCL17、IL-13、IL-22、IL-31、SCCA1/SCCA2和骨膜蛋白等,并讨论了其检测方法、分析验证参数和临床性能评估。传统标志物如总IgE、外周血嗜酸性粒细胞计数和类胰蛋白酶临床效用较低。实施需标准化皮肤样本采集、人群特异性参考区间、平台间协调和基于共识的临床意义临界值。

要点

  • TARC/CCL17、IL-13等新型标志物较总IgE等传统标志物更具临床效用。
  • 检测方法包括ELISA、珠基多重、邻近延伸和高灵敏数字方法。
  • 实施需标准化皮肤采样、参考区间、平台协调和共识临界值。

核心结论

  • 基于免疫分析的新型AD生物标志物可补充传统严重度评估,支持精准医学。

研究设计与样本

  • 叙述性综述,评估已具临床有效性的免疫分析生物标志物,样本包括血清、血浆及胶带剥离和微针采集的皮肤样本。

主要发现

  • TARC/CCL17、IL-13、IL-22、IL-31、SCCA1/SCCA2和骨膜蛋白等标志物用多种免疫分析检测。
  • 传统标志物总IgE、外周血嗜酸性粒细胞计数和类胰蛋白酶临床效用较低。
  • 分析验证参数包括检测限、定量限、可报告范围、精密度、线性、携带污染、方法比较、干扰评估、嗜异性抗体影响、校准和外部质量标准。
  • 临床性能评估采用曲线下面积(AUC)、似然比和决策限。

临床怎么用

  • 将可靠的AD生物标志物检测纳入现有诊断方法,以促进精准皮肤治疗和个性化护理。
  • 实施需标准化皮肤样本采集方法、人群特异性参考区间、平台间协调和基于共识的临床意义临界值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis (AD) is a persistent and recurring inflammatory skin condition that affects 204 million people worldwide, with prevalence rates of 11.1 % among children and 6.3 % among adults. This condition affects multiple systems, resulting in pruritus, skin barrier defects, and a Th2-driven immune imbalance, which consequently leads to significant costs and a diminished quality of life. To enhance precision medicine in laboratory diagnostics, it is essential to identify a neutral biomarker that can complement traditional severity assessments, such as SCORAD and EASI, for the diverse phenotypes and endotypes of AD. This narrative review examines immunoassay-based biomarkers with proven clinical validity in diagnostic laboratory medicine. Biomarkers such as TARC/CCL17, IL-13, IL-22, IL-31, SCCA1/SCCA2, and periostin are assessed using various tests, including ELISA, bead-based multiplexing, proximity extension, and highly sensitive digital methods. The samples included serum, plasma, and skin samples obtained through tape-stripping and microneedle collection. The parameters for analytical validation included detection and quantification limits, reportable range, precision, linearity, carryover effects, method comparison, interference assessment, heterophile antibody effects, calibration, and external quality standards. Clinical performance assessment uses measures such as the area under the curve (AUC), likelihood ratios, and decision limitations. Conventional biomarkers, including total IgE, peripheral eosinophil count, and tryptase, show less clinical utility than new biomarkers. Critical implementation requirements include standardized skin sample collection methods, population-specific reference intervals, inter-platform harmonization, and consensus-based cut-off values with clinical significance. This review outlines an evidence-based plan for incorporating reliable AD biomarker tests into current diagnostic methods to facilitate precise skin treatment and personalized care.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Orayj K, Samuel VP, Saleem S, et al. Immunoassay-based biomarkers in atopic dermatitis. Clin Chim Acta. 2025. PMID: 41067486. doi:10.1016/j.cca.2025.120634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。